MA33363B1 - Antagonistes de la voie de signalisation hedgehog a base de phtalazine disubstituee - Google Patents

Antagonistes de la voie de signalisation hedgehog a base de phtalazine disubstituee

Info

Publication number
MA33363B1
MA33363B1 MA34455A MA34455A MA33363B1 MA 33363 B1 MA33363 B1 MA 33363B1 MA 34455 A MA34455 A MA 34455A MA 34455 A MA34455 A MA 34455A MA 33363 B1 MA33363 B1 MA 33363B1
Authority
MA
Morocco
Prior art keywords
disubstituted
antagonists
phtalazine
signaling pathway
hedgehog signaling
Prior art date
Application number
MA34455A
Other languages
English (en)
French (fr)
Inventor
Philip Arthur Hipskind
Bharvin Kumar Patel
Nee Takakuwa Takako Wilson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA33363B1 publication Critical patent/MA33363B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA34455A 2009-06-19 2010-06-15 Antagonistes de la voie de signalisation hedgehog a base de phtalazine disubstituee MA33363B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21862809P 2009-06-19 2009-06-19
PCT/US2010/038568 WO2010147917A1 (en) 2009-06-19 2010-06-15 Disubstituted phthalazine hedgehog pathway antagonists

Publications (1)

Publication Number Publication Date
MA33363B1 true MA33363B1 (fr) 2012-06-01

Family

ID=42332981

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34455A MA33363B1 (fr) 2009-06-19 2010-06-15 Antagonistes de la voie de signalisation hedgehog a base de phtalazine disubstituee

Country Status (36)

Country Link
US (2) US8273742B2 (e)
EP (1) EP2443104B1 (e)
JP (1) JP5596139B2 (e)
KR (1) KR101389165B1 (e)
CN (1) CN102459233B (e)
AR (1) AR077014A1 (e)
AU (1) AU2010260244B2 (e)
BR (1) BRPI1011601A2 (e)
CA (1) CA2764542C (e)
CL (1) CL2011003147A1 (e)
CO (1) CO6480932A2 (e)
CR (1) CR20110658A (e)
DK (1) DK2443104T3 (e)
DO (1) DOP2011000386A (e)
EA (1) EA019059B1 (e)
EC (1) ECSP11011541A (e)
ES (1) ES2409054T3 (e)
HK (1) HK1164872A1 (e)
HN (1) HN2011003139A (e)
HR (1) HRP20130408T1 (e)
IL (1) IL216599A (e)
JO (1) JO2931B1 (e)
MA (1) MA33363B1 (e)
MX (1) MX2011014029A (e)
MY (1) MY156667A (e)
NZ (1) NZ596882A (e)
PE (1) PE20121050A1 (e)
PL (1) PL2443104T3 (e)
PT (1) PT2443104E (e)
SG (1) SG177289A1 (e)
SI (1) SI2443104T1 (e)
TN (1) TN2011000627A1 (e)
TW (1) TWI385165B (e)
UA (1) UA106755C2 (e)
WO (1) WO2010147917A1 (e)
ZA (1) ZA201108587B (e)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009241561B2 (en) * 2008-04-29 2013-05-16 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
US8404687B2 (en) * 2008-11-03 2013-03-26 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
KR101342184B1 (ko) 2008-11-17 2013-12-19 일라이 릴리 앤드 캄파니 사치환된 피리다진 헷지호그 경로 길항제
CA2743264C (en) * 2008-11-17 2014-02-18 Julia Marie Clay Tetrasubstituted pyridazines hedgehog pathway antagonists
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
CA2829755A1 (en) 2011-03-23 2012-09-27 Semorex Technologies Ltd. Treatment of proliferative disorders with a chemiluminescent agent
GB201309508D0 (en) * 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
GB201311953D0 (en) * 2013-07-03 2013-08-14 Redx Pharma Ltd Compounds
US9814703B2 (en) 2013-11-14 2017-11-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of BMP signaling
CN105017140B (zh) * 2014-04-28 2017-12-29 复旦大学 邻氨基苯甲酰胺化合物及其制备方法和用途
GB2528298A (en) * 2014-07-16 2016-01-20 Redx Pharma Plc Compounds
CN105985320B (zh) * 2015-02-11 2018-10-26 复旦大学 苄基酞嗪化合物及其制备方法和用途
CN105985319B (zh) * 2015-02-11 2019-02-26 复旦大学 芳基酞嗪化合物及其制备方法和用途
CN105985321B (zh) * 2015-02-11 2018-10-26 复旦大学 吡唑酞嗪化合物及其制备方法和用途
AU2016271468B2 (en) 2015-06-04 2020-01-02 Sol-Gel Technologies Ltd. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
WO2016196879A1 (en) * 2015-06-05 2016-12-08 Dana-Farber Cancer Institute, Inc. Compounds and methods for treating cancer
IL261721B (en) 2016-03-15 2022-07-01 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of solid tumors
CN106279114B (zh) * 2016-08-04 2019-01-29 东南大学 一种Taladegib的合成方法
US10548908B2 (en) * 2016-09-15 2020-02-04 Nostopharma, LLC Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification
CN106831718B (zh) * 2016-12-30 2019-05-07 上海科技大学 平滑受体配体及其应用
WO2018211007A1 (en) 2017-05-18 2018-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of mast cell diseases
KR20230031285A (ko) 2020-06-26 2023-03-07 라퀄리아 파마 인코포레이티드 레티노이드와 암 치료제의 병용 요법이 효과적인 암 환자를 선별하는 방법 및 레티노이드와 암 치료제의 병용 의약
EP4229828A1 (en) * 2020-10-13 2023-08-23 Endeavor Biomedicines, Inc. Methods of treating fibrosis

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN148482B (e) * 1977-06-03 1981-03-07 Pfizer
DK0876366T3 (da) 1996-01-15 2001-11-05 Janssen Pharmaceutica Nv Angiogenese-inhiberende pyridazinaminer
JP5067986B2 (ja) 1998-04-09 2012-11-07 ジョンズ ホプキンズ ユニヴァーシティー スクール オブ メディシン ヘッジホッグシグナリング経路の阻害剤としてのステロイドアルカロイド誘導体の使用
WO2000074706A1 (en) 1999-06-08 2000-12-14 Lorantis Limited Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway
CN1638765A (zh) * 2001-07-27 2005-07-13 柯里斯公司 Hedgehog信号转导途径介质、其相关组合物以及应用
WO2003088970A2 (en) * 2002-04-22 2003-10-30 Johns Hopkins University School Of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
WO2004020599A2 (en) 2002-08-29 2004-03-11 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
US8067608B2 (en) 2003-09-29 2011-11-29 The Johns Hopkins University Hedgehog pathway antagonists
TW200533356A (en) 2004-02-24 2005-10-16 Mitsubishi Pharma Corp Fused pyridazine derivatives
US8338591B2 (en) 2004-05-08 2012-12-25 Novartis International Pharmaceutical Ltd. 3-aryl-5,6-disubstituted pyridazines
UA96565C2 (ru) 2004-09-02 2011-11-25 Дженентек, Инк. Пиридильные ингибиторы хеджхоговской передачи сигнала
EP1900731A1 (de) * 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
MY156814A (en) 2007-03-15 2016-03-31 Novartis Ag Organic compounds and their uses
AU2008269128B2 (en) 2007-06-25 2012-08-02 Amgen Inc. Phthalazine compounds, compositions and methods of use
EP2188283B1 (en) 2007-09-07 2012-08-15 Amgen Inc. Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling
BRPI0820856A2 (pt) * 2007-12-13 2019-05-14 Siena Bhiotech.S.P.A. anatagonista da série de reação de hedgehog e aplicações terapêuticas dos mesmos
AU2009241561B2 (en) 2008-04-29 2013-05-16 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
US20110301162A1 (en) * 2008-08-04 2011-12-08 Amgen Inc. Aurora kinase modulators and methods of use
US8404687B2 (en) 2008-11-03 2013-03-26 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
KR101342184B1 (ko) 2008-11-17 2013-12-19 일라이 릴리 앤드 캄파니 사치환된 피리다진 헷지호그 경로 길항제
CA2743264C (en) 2008-11-17 2014-02-18 Julia Marie Clay Tetrasubstituted pyridazines hedgehog pathway antagonists
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer

Also Published As

Publication number Publication date
HRP20130408T1 (en) 2013-06-30
UA106755C2 (uk) 2014-10-10
AU2010260244B2 (en) 2013-09-05
SI2443104T1 (sl) 2013-07-31
DK2443104T3 (da) 2013-05-06
DOP2011000386A (es) 2012-02-29
CN102459233A (zh) 2012-05-16
CR20110658A (es) 2012-02-20
CL2011003147A1 (es) 2012-07-20
NZ596882A (en) 2013-08-30
US9000023B2 (en) 2015-04-07
AR077014A1 (es) 2011-07-27
EA019059B1 (ru) 2013-12-30
US20120316174A1 (en) 2012-12-13
US8273742B2 (en) 2012-09-25
PE20121050A1 (es) 2012-08-09
EP2443104B1 (en) 2013-04-17
CA2764542C (en) 2013-09-10
HK1164872A1 (en) 2012-09-28
ES2409054T3 (es) 2013-06-24
JO2931B1 (en) 2015-09-15
CO6480932A2 (es) 2012-07-16
TN2011000627A1 (en) 2013-05-24
SG177289A1 (en) 2012-02-28
PT2443104E (pt) 2013-05-07
CA2764542A1 (en) 2010-12-23
US20100324048A1 (en) 2010-12-23
MX2011014029A (es) 2012-02-21
HN2011003139A (es) 2013-07-29
TWI385165B (zh) 2013-02-11
JP5596139B2 (ja) 2014-09-24
CN102459233B (zh) 2014-07-02
PL2443104T3 (pl) 2013-08-30
KR101389165B1 (ko) 2014-04-24
KR20120024783A (ko) 2012-03-14
IL216599A (en) 2015-09-24
TW201113268A (en) 2011-04-16
ECSP11011541A (es) 2012-01-31
JP2012530705A (ja) 2012-12-06
EA201270049A1 (ru) 2012-05-30
BRPI1011601A2 (pt) 2016-03-22
MY156667A (en) 2016-03-15
WO2010147917A1 (en) 2010-12-23
ZA201108587B (en) 2013-05-29
IL216599A0 (en) 2012-03-01
AU2010260244A1 (en) 2012-01-19
EP2443104A1 (en) 2012-04-25

Similar Documents

Publication Publication Date Title
MA33363B1 (fr) Antagonistes de la voie de signalisation hedgehog a base de phtalazine disubstituee
MA32726B1 (fr) Antagonistes phtalazine disubstituee de la voie de signalisation hedgehog
MA33244B1 (fr) Composes de vinylindazolyle
MA33224B1 (fr) Derives de proline comme inhibiteurs de la cathepsine
PA8713501A1 (es) INHIBIDORES DE 11-BETA HIDROXIESTEROIDE DEHIDROGENASA - 11ßHSD1
MA32349B1 (fr) Antagonistes de la voie hedgehog a base de phtalazines disubstituees
EA201201665A1 (ru) Новые соединения
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
UY32820A (es) Composiciones dermatologicas de antagonistas del receptor dp2
MA33492B1 (fr) Inhibiteurs de bace
EA201171211A1 (ru) Производные оксадиазола
TNSN08337A1 (fr) Piperidinoylpyrrolidines agonistes du recepteur de melanocortine de type 4
BRPI0814772A2 (pt) Indazóis substituídos por 5-piridinona
FR2981934B1 (fr) Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
MA31701B1 (fr) Depsipeptides cycliques
ECSP099560A (es) Nuevo procedimiento de síntesis de la agomelatina
DE602006015686D1 (de) Als agonisten des gpr38-rezeptors geeignete biarylverbindungen
MA33824B1 (fr) Agonistes du recepteur mglu2
UY31883A (es) Nuevo procedimiento de síntesis de 7,8-dimetoxi-1, 3-dihidro-2h-3-benzazepin-2-ona, y aplicación en la síntesis de ivabradina y de sus sales de adición a un ácido farmacéuticamente aceptable
EA200801549A1 (ru) Новые производные фенантридина в качестве антагонистов брадикинина
TN2012000301A1 (fr) Utilisation du 2,3-dihydroxypropyl dodécanoate pour le traitement de la séborrhée
FR2981936B1 (fr) Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
UA108126C2 (uk) Спосіб отримання співполімеру натрійкарбоксиметилцелюлози й госиполу
RU2008116559A (ru) Хлорсодержащие ароматические олигоэфиры
FR2905600B1 (fr) Traitement des vertiges par l'acetyl-l-leucine.